Xencor Inc XNCR Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$35.75 up $1.70, 4.99% at close Nov 6
Last close · Previous close $34.05
- Market cap
- At the Nov 6 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$1.59Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$35.75up $1.70, 4.99%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$34.05Nov 5
- Volume1.12MNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume1.78MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $10.38 to $36.50; now $35.75
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
XNCR beat the S&P 500 in 5 of 7 periods.
| Period | XNCR and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | XNCR: up 46.8% S&P 500: down 5.6% | XNCR beat the S&P 500 by 52.4 percentage points Beat |
| 3M | XNCR: up 78.8% S&P 500: down 4.1% | XNCR beat the S&P 500 by 82.9 percentage points Beat |
| YTD | XNCR: up 133.5% S&P 500: up 8.7% | XNCR beat the S&P 500 by 124.8 percentage points Beat |
| 1Y | XNCR: up 155.4% S&P 500: up 10.9% | XNCR beat the S&P 500 by 144.5 percentage points Beat |
| Long term | ||
| 3Y | XNCR: up 94.3% S&P 500: up 75.0% +24.8% vs +20.5% a year | XNCR beat the S&P 500 by 19.3 percentage points Beat |
| 5Y | XNCR: down 13.4% S&P 500: up 67.8% −2.8% vs +10.9% a year | XNCR trailed the S&P 500 by 81.2 percentage points Trailed |
| 10Y | XNCR: up 84.7% S&P 500: up 313.1% +6.3% vs +15.2% a year | XNCR trailed the S&P 500 by 228.4 percentage points Trailed |
$10,000 invested in XNCR 10 years ago (Nov 4, 2016) would be worth about $18,466 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
XNCR beat the S&P 500 in 5 of 7 periods.
| Period | XNCR and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | XNCR: up 46.8% S&P 500: down 5.6% | XNCR beat the S&P 500 by 52.4 percentage points Beat |
| 3M | XNCR: up 78.8% S&P 500: down 4.3% | XNCR beat the S&P 500 by 83.1 percentage points Beat |
| YTD | XNCR: up 133.5% S&P 500: up 7.8% | XNCR beat the S&P 500 by 125.7 percentage points Beat |
| 1Y | XNCR: up 155.4% S&P 500: up 9.7% | XNCR beat the S&P 500 by 145.7 percentage points Beat |
| Long term | ||
| 3Y | XNCR: up 94.3% S&P 500: up 68.8% +24.8% vs +19.1% a year | XNCR beat the S&P 500 by 25.5 percentage points Beat |
| 5Y | XNCR: down 13.4% S&P 500: up 56.9% −2.8% vs +9.4% a year | XNCR trailed the S&P 500 by 70.3 percentage points Trailed |
| 10Y | XNCR: up 84.7% S&P 500: up 252.6% +6.3% vs +13.4% a year | XNCR trailed the S&P 500 by 167.9 percentage points Trailed |
$10,000 invested in XNCR 10 years ago (Nov 4, 2016) would be worth about $18,466 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$53.88
Closing high on . Now 33.6% below that record.
Split-adjusted daily closes since Dec 3, 2013.
Stock splits
XNCR hasn’t split since its price history begins in 2013.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q3 FY26, the quarter ended Sep 30, 2026. “Last 12 months” means the four quarters from Oct 1, 2025 to Sep 30, 2026, and balance-sheet figures are as of Sep 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $200.49Mup 33.5%
- Net income
- −$117.86M
- Diluted EPS
- −$1.59
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q4 FY24 (Dec 31, 2024) | $52.79M | −$45.55M | −$0.58 |
| Q1 FY25 (Mar 31, 2025) | $32.73M | −$48.42M | −$0.66 |
| Q2 FY25 (Jun 30, 2025) | $43.61M | −$30.83M | −$0.41 |
| Q3 FY25 (Sep 30, 2025) | $21.00M | −$6.03M | −$0.08 |
| Q4 FY25 (Dec 31, 2025) | $28.24M | −$6.65M | −$0.09 |
| Q1 FY26 (Mar 31, 2026) | $4.52M | −$128.92M | −$1.71 |
| Q2 FY26 (Jun 30, 2026) | $51.22M | −$21.73M | −$0.29 |
| Q3 FY26 (Sep 30, 2026) | $116.52M | $39.44M | $0.50 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $275.11M | $82.63M | $1.37 |
| FY22 (Dec 31, 2022) | $164.58M | −$55.18M | −$0.93 |
| FY23 (Dec 31, 2023) | $174.62M | −$133.13M | −$2.20 |
| FY24 (Dec 31, 2024) | $110.49M | −$232.62M | −$3.58 |
| FY25 (Dec 31, 2025) | $125.58M | −$91.92M | −$1.24 |
Margins
- Gross 100.0%
- Operating −72.7%
- Net −58.8%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$176.45MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$172.36MLast 12 months
- Capital spending$4.09MLast 12 months
- −88.0%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $18.29MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $585.85MAs of Sep 30, 2026
Cash plus short- and long-term marketable securities on the Sep 30, 2026 balance sheet.
- Total debt$160.23MAs of Sep 30, 2026
- Net cash$425.63MAs of Sep 30, 2026
- 6.54As of Sep 30, 2026
Current assets divided by current liabilities on the Sep 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.29As of Sep 30, 2026
Total debt divided by shareholders’ equity on the Sep 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 3 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✗Return on assets improved: not passed
- ✗Operating cash flow exceeded net income: not passed
- ✓Long-term debt fell relative to assets: passed
- ✓Current ratio improved: passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- −21.3%Last 12 months
Over the last 12 months, Xencor lost money: its net loss was 21.3% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −15.2%Last 12 months
Over the last 12 months, Xencor’s net loss was 15.2% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Xencor Inc
Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and multiple XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein’s structure that result in new mechanisms of therapeutic action.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- California, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
XNCR news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
XNCR stock FAQ
What is XNCR stock’s price today?
Xencor (XNCR) traded at $35.75 at the close on , up $1.70 (4.99%) from the previous close of $34.05. Over the past 52 weeks it has traded between $10.38 and $36.50.
If you invested $1,000 in XNCR 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in XNCR on would be worth about $1,847 at the close on , a total return of +84.7%. The same $1,000 would be worth $866 if invested five years ago and $2,554 if invested one year ago. Past performance doesn’t predict future returns.
What is XNCR’s P/E ratio?
XNCR’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$1.59).
How much revenue does Xencor make?
Xencor reported $200.5 million of revenue over the four quarters to , up 33.5% from the twelve months before. In its latest quarter (Q3 FY26, ended ) revenue was $116.5 million, up 454.9% from a year earlier.
Is Xencor profitable?
Not over the four quarters to . Xencor reported a net loss of $117.9 million across those four quarters on $200.5 million of revenue.
What are XNCR’s earnings per share?
XNCR’s diluted earnings per share were −$1.59 over the four quarters to , compared with −$1.73 in the twelve months before. The latest quarter (Q3 FY26) brought $0.50 per share, against −$0.08 a year earlier (how EPS works).
Does XNCR pay a dividend?
Xencor hasn’t paid a dividend in the last twelve months.
What is XNCR’s 52-week high and low?
Over the past 52 weeks XNCR has traded as low as $10.38 and as high as $36.50. At $35.75 at the close on , it is 2.1% below that high and 244.6% above the low.
What is XNCR’s all-time high?
XNCR’s highest closing price was $53.88 on , adjusted for stock splits. At $35.75 at the close on , it is 33.6% below that record.
Has XNCR stock ever split?
No. XNCR hasn’t split since its price history begins in 2013.
How has XNCR stock performed?
Including dividends and measured to the close on , XNCR has returned +133.5% so far this year and +155.4% over the past year, and −13.4% over five years (−2.8% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Xencor in?
Xencor is in the Healthcare sector and the Biotechnology industry, and is headquartered in California, USA.
What exchange does XNCR trade on?
Xencor trades on the Nasdaq under the ticker symbol XNCR. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.